Insulet vs DexCom vs West Pharmaceutical Services Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q1 2026: Insulet 0.762, DexCom 1.192, West Pharmaceutical Services 0.872.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Insulet, DexCom, West Pharmaceutical Services.| Metric | Insulet | DexCom | West Pharmaceutical Services |
|---|---|---|---|
| Market Cap | $11.48B | $28.76B | $23.90B |
| Revenue | $762.00M | $1.19B | $872.00M |
| Cost of Revenue | $233.00M | $442.00M | $543.00M |
| Gross Profit | $529.00M | $750.00M | $329.00M |
| Operating Income | $122.00M | $255.00M | $179.00M |
| Net Income | $91.00M | $200.00M | $154.00M |
| R&D Expense | $90.00M | $145.00M | $20.00M |
| Earnings Per Share | $1.3 | $0.51 | $2.15 |
| Gross Margin | 69.5% | 63.0% | 37.7% |
| Operating Margin | 16.0% | 21.4% | 20.5% |
| Net Profit Margin | 12.0% | 16.7% | 17.6% |
| Free Cash Flow | $86.00M | $449.00M | $81.00M |
| Cumulative Free Cash Flow | $-97.00M | $3.21B | $3.60B |
| Operating Cash Flow | $114.00M | $526.00M | $124.00M |
| Cash & Equivalents | $480.00M | $1.12B | $436.00M |